A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis

Inclusion Criteria Patients must have: * HIV positive or negative status. * Blastomycosis or histoplasmosis. * Life expectancy of at least 1 week. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Liver disease. * Self-limiting fungal disease. * Very severe fungal disease such as meningeal involvement. * Acute respiratory disease. Concurrent Medication: Excluded at any time: * Terfenadine. * Astemizole. * Oral midazolam. * Triazolam. * Cisapride. * Phenytoin. * Phenobarbital. * Rifampin. * Rifabutin. Excluded during oral consolidation: * H2 blockers. * Chronic antacids. * Omeprazole. * Lansoprazole. Patients with the following prior condition are excluded: Hypersensitivity to azole antifungals. Prior Medication: Excluded at any time: More than 3 days of amphotericin B, fluconazole, or ketoconazole. Excluded within 2 weeks prior to study entry: * Phenytoin. * Phenobarbital. * Rifampin. * Rifabutin.